6 results
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Guidelines - Table ... infection Episode #Pharmacology ... #Clostridium #CDifficile ... IDSA2017 #Adjunct #Antibiotics
Clostridium Dificile Risk by Antibiotic Class

Pooled and study-specific risk estimates of community-associated CDI risk by antibiotic
Clostridium Dificile ... #CDifficile #Infection ... #Pharmacology # ... #Clostridium #Table ... #Comparison #OddsRatio
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... if MIC<0.12 ug/ml ... Treating Clostridium difficile ... Enteric #Bacterial #IDSA ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... chew, or crush tablet ... suspension 4–6 mL ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
Potential Treatment Agents for Treatment of the Primary Clostridium difficile infection Episode
Proven efficacy:
 • Vancomycin -
Primary Clostridium difficile ... × 10 days #CDiff ... treatment #management #pharmacology ... #idsa #table
IDSA Recommended Dosages of Antimicrobial Agents Administered by the Intraventricular Route
Amikacin - 5–50 mg
Amphotericin B -
IDSA Recommended ... Intraventricular #antibiotics ... #dosing #pharmacology ... ventriculitis #table ... #idsa